S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NYSEAMERICAN:HLTH

Nobilis Health Stock Forecast, Price & News

$11.46
-0.59 (-4.90%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.88
$12.29
50-Day Range
N/A
52-Week Range
$8.53
$22.55
Volume
685,447 shs
Average Volume
940,361 shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive HLTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Nobilis Health and its competitors with MarketBeat's FREE daily newsletter.


Nobilis Health logo

About Nobilis Health

Nobilis Health Corp. owns and manages ambulatory surgical centers (ASCs), and acute-care and surgical hospitals in the United States. It operates through two segments, Medical Services and Marketing. The company's healthcare facilities provides surgical procedures in various clinical specialties, including orthopedic surgery, podiatric, vein and vascular, pain management, gastro- intestinal, gynecology, and general, as well as ear, nose, and throat. It also provides marketing services, patient education services, and patient care co-ordination management services to third party facilities and physicians. As of December 4, 2017, it operated 32 locations, including 5 hospitals, 14 ASCs, and 13 multi-specialty clinics. The company was formerly known as Northstar Healthcare Inc. and changed its name to Nobilis Health Corp. in December 2014. Nobilis Health Corp. was founded in 2007 and is based in Houston, Texas.

Headlines

Nobilis Health (NYSEAMERICAN:HLTH) Shares Gap Down to $11.02
December 2, 2021 |  americanbankingnews.com
Nobilis Health (NYSEAMERICAN:HLTH) Shares Gap Up to $11.45
November 29, 2021 |  americanbankingnews.com
Nobilis Health (NYSEAMERICAN:HLTH) Trading Up 7.7%
November 24, 2021 |  americanbankingnews.com
Nobilis Health (NYSEAMERICAN:HLTH) Stock Price Down 7.3%
November 19, 2021 |  americanbankingnews.com
Nobilis Health (NYSEAMERICAN:HLTH) Trading 6.1% Higher
November 15, 2021 |  americanbankingnews.com
Nobilis Health (NYSEAMERICAN:HLTH) Stock Price Down 5.1%
November 11, 2021 |  americanbankingnews.com
Nobilis Health (NYSEAMERICAN:HLTH) Trading 7.2% Higher
November 9, 2021 |  americanbankingnews.com
Nobilis Health (HLTH) Stock
August 19, 2020 |  markets.businessinsider.com
Nobilis Health Corp - Profile
August 17, 2020 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:HLTH
Phone
N/A
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.68 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/04/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.55 out of 5 stars

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Nobilis Health (NYSEAMERICAN:HLTH) Frequently Asked Questions

Is Nobilis Health a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nobilis Health in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nobilis Health stock.
View analyst ratings for Nobilis Health
or view top-rated stocks.

How were Nobilis Health's earnings last quarter?

Nobilis Health Corp (NYSEAMERICAN:HLTH) posted its quarterly earnings data on Wednesday, November, 10th. The healthcare company reported $0.13 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.40 by $1.27.
View Nobilis Health's earnings history
.

What guidance has Nobilis Health issued on next quarter's earnings?

Nobilis Health updated its FY 2021 earnings guidance on Wednesday, December, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $580 million-$590 million, compared to the consensus revenue estimate of $541.29 million.

What price target have analysts set for HLTH?

4 analysts have issued twelve-month price objectives for Nobilis Health's shares. Their forecasts range from $12.00 to $19.00. On average, they anticipate Nobilis Health's stock price to reach $15.75 in the next year. This suggests a possible upside of 37.4% from the stock's current price.
View analysts' price targets for Nobilis Health
or view top-rated stocks among Wall Street analysts.

Who are Nobilis Health's key executives?

Nobilis Health's management team includes the following people:
  • Mr. Harry Joseph Fleming, Chairman (Age 60)
  • Dr. Kenneth D. Efird, Pres (Age 39)
  • Mr. Patrick Yoder, Chief Revenue Officer (Age 41)
  • Dr. Neil Badlani, Chief Medical Officer & Director (Age 40)
  • Ms. Marissa Arreola, Chief Strategy Officer & Pres of Concertis (Age 46)

What other stocks do shareholders of Nobilis Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nobilis Health investors own include Chesapeake Energy (CHKAQ), (CATB), 217932 (NHC.TO) (NHC), Enerplus (ERF), Palatin Technologies (PTN), Quarterhill (QTRH), Argonaut Gold (AR), Gilead Sciences (GILD), Prospect Capital (PSEC) and Abeona Therapeutics (ABEO).

What is Nobilis Health's stock symbol?

Nobilis Health trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HLTH."

When did the company's quiet period expire?

Nobilis Health's quiet period expired on Wednesday, November 3rd. Nobilis Health had issued 12,500,000 shares in its initial public offering on September 24th. The total size of the offering was $200,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Nobilis Health's major shareholders?

Nobilis Health's stock is owned by many different retail and institutional investors. Top institutional investors include Johnson & Johnson (3.79%), Jabodon PT Co. (3.49%), Temasek Holdings Private Ltd (2.17%), Naya Capital Management UK Ltd. (1.69%), Capital World Investors (1.65%) and Perceptive Advisors LLC (1.08%).
View institutional ownership trends for Nobilis Health
.

Which major investors are buying Nobilis Health stock?

HLTH stock was acquired by a variety of institutional investors in the last quarter, including Johnson & Johnson, Jabodon PT Co., Temasek Holdings Private Ltd, Naya Capital Management UK Ltd., Capital World Investors, Perceptive Advisors LLC, Foresite Capital Management V LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Nobilis Health
or or view top insider-buying stocks.

How do I buy shares of Nobilis Health?

Shares of HLTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nobilis Health's stock price today?

One share of HLTH stock can currently be purchased for approximately $11.46.

How much money does Nobilis Health make?

Nobilis Health has a market capitalization of $1.68 billion.

How many employees does Nobilis Health have?

Nobilis Health employs 2,021 workers across the globe.

What is Nobilis Health's official website?

The official website for Nobilis Health is www.northstar-healthcare.com.

Where are Nobilis Health's headquarters?

How can I contact Nobilis Health?

Nobilis Health's mailing address is 11700 Katy Fwy Ste 300, HOUSTON, TX 77079-1218, United States. The healthcare company can be reached via email at [email protected].


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.